ArticleScientific reports2025
Impact of local therapy in metastatic renal cell carcinoma during medical treatment in a retrospective analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oligoprogressive renal cell carcinoma: What is the role of surgery?BJU international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current guidelines on treatment of metastatic renal cell carcinoma (mRCC) suggest an emerging role of local therapy (LT). Still there is a lack of data which patients may benefit from additional LT once medical treatment (MT) is initiated. We retrospectively aim to characterize LT in patients with mRCC who underwent LT while receiving MT. 315/401 mRCC patients were eligible, thereof 163 (51.7%) received LT during MT (LT( +)), while 152 (48.3%) received only MT (LT(-)). Radiotherapy (49.1%) and surgery (41.7%) were the most frequently administered LT modalities. Overall survival (OS) was not superior in LT( +) vs. LT(-) (35.9, (95%-CI [confidence interval]: 29.8-42.0) vs. 20.3, (95%-CI: 10.3-30.3) months, log-rank p = 0.117). However, in a subgroup analysis the duration of MT prior to initiation of LT (≤ 6 months 24.1 (95%-CI: 18.6-29.6) vs. > 6 months: 43.0 (95%-CI: 32.2-36.2) months, log-rank p = 0.005) and the type of progression (oligoprogression: 44.0 (95%-CI: 31.5-56.5) vs. systemic progression: 29.6 (95%-CI: 23.4-35.8) months, log-rank p = 0.03) were associated with improved OS. We present the largest analysis of LT during MT. Our study has enhanced our understanding of LT utilization in mRCC after MT is already initiated. Ultimately, the inclusion of LT could improve OS in selected patients receiving MT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.